Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate’s Ability to Block H5N1 Bird Flu Virus
BOSTON, MA / ACCESS Newswire / February 23, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georg…
Continue Reading